Novo Nordisk A/S – Share repurchase programme
November 29 2021 - 10:19AM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark,
29 November
2021 – On 5 November 2021, Novo Nordisk initiated
a share repurchase programme in accordance with Article 5 of
Regulation No 596/2014 of the European Parliament and Council of 16
April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This
programme is part of the overall share repurchase programme of up
to DKK 20 billion to be executed during a 12-month period beginning
3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk will
repurchase B shares for an amount up to DKK 3.7 billion in the
period from 11 November 2021 to 1 February 2022.
Since the announcement 22 November 2021, the following
transactions have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
Accumulated, last announcement |
703,000 |
|
523,952,190 |
22 November
2021 |
100,000 |
750.13 |
75,013,122 |
23 November
2021 |
105,000 |
722.27 |
75,837,883 |
24 November
2021 |
105,000 |
724.71 |
76,094,782 |
25 November
2021 |
95,000 |
722.82 |
68,668,365 |
26 November
2021 |
95,000 |
711.40 |
67,582,806 |
Accumulated under the programme |
1,203,000 |
|
887,149,148 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
29,392,732 B shares of DKK 0.20 as treasury shares, corresponding
to 1.3% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 3 February 2021.
As of 26 November 2021, Novo Nordisk has since 3 February 2021
repurchased a total of 30,639,181 B shares at an average share
price of DKK 560.81 per B share equal to a transaction value of DKK
17,182,675,592.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 77 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024